Complementary therapeutic effects of dual delivery of insulin-like growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure

European Journal of Heart Failure

Volumn 13, Issue 12, 2011, Pages 1264-1274

  Cittadini, Antonio ^a   Monti, Maria Gaia ^a   Petrillo, Valentina ^a   Esposito, Giovanni ^a   Imparato, Giorgia ^a,b   Luciani, Alessia ^b,c   Urciuolo, Francesco ^b,c   Bobbio, Emanuele ^a   Natale, Carlo F ^a,b   Sacc, Luigi ^a   Netti, Paolo A ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c CNR   (Italy)

Author keywords

Gelatin microspheres; IGF 1; Myocardial infarction; VEGF

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATIN; MAMMALIAN TARGET OF RAPAMYCIN; MICROSPHERE; PROTEIN KINASE B; RECOMBINANT SOMATOMEDIN C; RECOMBINANT VASCULOTROPIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG RELEASE; ENDOPLASMIC RETICULUM; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART MUSCLE CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT DURATION;

ABSORBABLE IMPLANTS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; GELATIN; HEART CATHETERIZATION; IMMUNOHISTOCHEMISTRY; INJECTIONS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICROSPHERES; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 81855194760     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr143     Document Type: Article

References (35)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-1172. (Pubitemid 20119612)
2. Shah AM, Solomon SD. A unified view of ventricular remodeling. Eur J Heart Fail 2010;12:779-781.
3. Misra A, Mann DL. Treatment of heart failure beyond practice guidelines. Role of cardiac remodeling. Circ J 2008;72:A1-A7.
4. Ross J Jr, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail 1996;2:S121-S128. (Pubitemid 126686399)
5. Saccà L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994;15: 555-573. (Pubitemid 24328207)
6. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di Gianni A, Serpico R, Iaccarino G, Saccà L. GH prolongs survival in experimental postinfarction heart failure. J Am Coll Cardiol 2003;41:2154-2163. (Pubitemid 36733540)
7. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95:619-627.
8. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100:1991-1999. (Pubitemid 27459352)
9. Su EJ, Cioffi CL, Stefansson S, Mittereder N, Garay M, Hreniuk D, Liau G. Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization. Am J Physiol Heart Circ Physiol 2003;284:H1429-H1440. (Pubitemid 36348607)
10. Cittadini A, Grossman J, Napoli R, Katz SE, Stromer H, Smith RJ, Clark R, Morgan JP, Douglas PS. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997;29:1109-1116. (Pubitemid 27149590)
11. Zhang J, Ding L, Zhao Y, Sun W, Chen B, Lin H, Wang X, Zhanq L, Xu B, Dai J. Collagen-targeting VEGF improves cardiac performance after myocardial infarction. Circulation 2009;119:1776-1784.
12. Ruixing Y, Dezhai Y, Hai W, Kai H, Xianghong W, Yuming C. Intramyocardial injection of vascular endothelial growth factor gene improves cardiac performance and inhibits cardiomyocyte apoptosis. Eur J Heart Fail 2007;9:343-351. (Pubitemid 46441972)
13. Yockman JW, Choi D, Whitten M, Chang CW, Kastenmeier A, Erickson H, Albanil A, Lee M, Kim SW, Bull DA. Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Ther 2009;16:127-135.
14. Hao X, Silva EA, Mansonn-Broberg A, Grinnemo KH, Siddiqui AJ, Waedell E, Brodin LA, Mooney DJ, Sylvén C. Angiogenic effect of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 2007;75:178-185. (Pubitemid 46876668)
15. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996;270:H1803-H1811.
16. Post MJ, Laham R, Sellke FW, Simons M. Therapeutic angiogenesis in cardiology using protein formulation. Cardiovasc Res 2001;49:522-531. (Pubitemid 32146415)
17. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression Circulation 2000;102:898-901.
18. Hoshino K, Kimura T, De Grand AM, Yoneyama R, Kawase Y, Houser S, Ly HQ, Kushibiki T, Furukawa Y, Ono K, Tabata Y, Frangioni JV, Kita T, Hajjar RJ, Hayase M. Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres. Gene Ther 2006;13:1320-1327. (Pubitemid 44323688)
19. Anderl JN, Robey TE, Stayton PS, Murry CE. Retention and biodistribution of microspheres injected into ischemic myocardium. J Biomed Mater Res A 2009; 88:704-710.
20. NakaseH, Okazaki K, Tabata Y, Ozeki M,Watanabe N, Ohana M, Uose S, Uchida K, Nishi T, MastuuraM, Tamaki H, Itoh T, Kawanami C, Chiba T. Newcytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther 2002;301:59-65. (Pubitemid 34250279)
21. Tabata Y, Hijikata S, Muniruzzaman M, Ikada Y. Neovascularization effect of biodegradable gelatin microspheres incorporating basic fibroblast growth factor. J Biomater Sci Polym Ed 1999;10:79-94. (Pubitemid 29097233)
22. Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, Tabata Y. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003;18:93-99. (Pubitemid 36701553)
23. Chimenti I, Ruckdeschel Smith R, Li TS, Gerstenblith G, Messina E, Giacomello A, Marbàn E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res 2010;106: 971-980.
24. Cittadini A, Monti MG, Isgaard J, Casaburi C, Strömer H, Di Gianni A, Serpico R, Saldamarco L, Vanasia M, Saccà L. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003;58:555-564. (Pubitemid 36694441)
25. D'Ascia C, Cittadini A, Monti MG, Riccio G, Saccà L. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium Eur Heart J 2006;27:201-206. (Pubitemid 43069038)
26. Grundtman C, Hollan I, Førre OT, Saatvedt K, Mikkelsen K, Lundberg IE. Cardiovascular disease in patients with inflammatory rheumatic disease is associated with up-regulation of markers of inflammation in cardiac microvessels and cardiomyocytes. ArthritisRheum 2010;62:667-673.
27. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74:86-107. (Pubitemid 26041012)
28. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci W, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118. (Pubitemid 41134152)
29. Zhu XH, Tabata Y, Wang CH, Tong YW. Delivery of basic fibroblast growth factor from gelatin microsphere scaffold for the growth of human umbilical vein endothelial cells. Tissue Eng Part A 2008;12:1939-1947.
30. Putnam D. Drug delivery The heart of the matter. Nat Mater 2008;7:836-837.
31. Chaanine AH, Hajjar RJ. AKT signaling in the failing heart. Eur J Heart Fail 2011;13: 825-829.
32. Yau TM, Kim C, Guangming L, Zhang Y,Weisel RD, Li R-K. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 2005;112:I123-I128. (Pubitemid 41266663)
33. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008;103:1204-1219.
34. Abbate A, Biondi-Zoccai GGL, Baldi A. Cellular preservation therapy in heart failure. Am J Physiol Heart Circ Physiol 2009;296:H563-H565.
35. Sadat S, Gehmert S, Song YH, Yen Y, Bai X, Gaiser S, Klein H, Alt E. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007; 363:674-679. (Pubitemid 47513683)